ArticleAmerican journal of cancer research2026

Survival outcomes and safety of adding high-dose-rate intraluminal brachytherapy (HDR-ILBT) utilizing the novel balloon applicator (BRAXX) following concurrent chemoradiotherapy (CCRT) for non-surgical esophageal cancer: a prospective pilot and real-world comparative study.

Sean Hsiang-Ting Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.